JP2024527539A5 - - Google Patents

Info

Publication number
JP2024527539A5
JP2024527539A5 JP2023580404A JP2023580404A JP2024527539A5 JP 2024527539 A5 JP2024527539 A5 JP 2024527539A5 JP 2023580404 A JP2023580404 A JP 2023580404A JP 2023580404 A JP2023580404 A JP 2023580404A JP 2024527539 A5 JP2024527539 A5 JP 2024527539A5
Authority
JP
Japan
Prior art keywords
seq
immune effector
sequence shown
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/103037 external-priority patent/WO2023274380A1/zh
Publication of JP2024527539A publication Critical patent/JP2024527539A/ja
Publication of JP2024527539A5 publication Critical patent/JP2024527539A5/ja
Pending legal-status Critical Current

Links

JP2023580404A 2021-07-01 2022-06-30 IL13Rα2を標的としたユニバーサルCAR-T細胞及びその製造方法と使用 Pending JP2024527539A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110749536 2021-07-01
CN202110749536.3 2021-07-01
PCT/CN2022/103037 WO2023274380A1 (zh) 2021-07-01 2022-06-30 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用

Publications (2)

Publication Number Publication Date
JP2024527539A JP2024527539A (ja) 2024-07-25
JP2024527539A5 true JP2024527539A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=84690444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580404A Pending JP2024527539A (ja) 2021-07-01 2022-06-30 IL13Rα2を標的としたユニバーサルCAR-T細胞及びその製造方法と使用

Country Status (5)

Country Link
US (1) US20240376216A1 (cg-RX-API-DMAC7.html)
EP (1) EP4364746A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527539A (cg-RX-API-DMAC7.html)
CN (1) CN115768445A (cg-RX-API-DMAC7.html)
WO (1) WO2023274380A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118255887A (zh) * 2023-08-03 2024-06-28 森妙生物科技(西安)有限公司 一种抗体或其抗原结合片段及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
KR101763499B1 (ko) 2012-11-07 2017-07-31 화이자 인코포레이티드 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
US20150037304A1 (en) * 2013-03-12 2015-02-05 Sangamo Biosciences, Inc. Methods and compositions for modification of hla
EP3673732A3 (en) * 2015-10-27 2020-07-29 Recombinetics, Inc. Engineering of humanized car t-cells and platelets by genetic complementation
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
US12083148B2 (en) * 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
WO2019006072A1 (en) * 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS
WO2019014581A1 (en) * 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
CN109456943A (zh) * 2017-09-06 2019-03-12 亘喜生物科技(上海)有限公司 通用型嵌合抗原受体t细胞制备技术
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
WO2019126774A1 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Novel crispr enzymes and systems
JP7438123B2 (ja) * 2018-03-14 2024-02-26 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体
EP3824075A4 (en) * 2018-07-17 2022-04-20 The Regents of The University of California CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
EP4003407A1 (en) * 2019-07-23 2022-06-01 Mnemo Therapeutics Immune cells defective for suv39h1
US20210128617A1 (en) * 2019-08-27 2021-05-06 The Trustees Of The University Of Pennsylvania SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
JP7670358B2 (ja) * 2020-01-02 2025-04-30 寧波茂行生物医薬科技有限公司 修飾された免疫エフェクター細胞及びその調製方法
US11965022B2 (en) * 2020-12-31 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
AU2022301099A1 (en) * 2021-07-01 2024-02-15 Ningbo T-Maximum Biopharmaceuticals Co., Ltd. Antigen-binding polypeptide targeting b7h3 and application thereof
JP2024527537A (ja) * 2021-07-01 2024-07-25 寧波茂行生物医薬科技有限公司 Gd2を標的とするユニバーサルcar-t細胞及びその製造方法並びに使用

Similar Documents

Publication Publication Date Title
WO2021037037A1 (en) Novel anti-cd39 antibodies
CN107108747B (zh) 具有共同轻链的双特异性抗体或抗体混合物
AU2017379382B9 (en) Anti-CD3 Antibody and Molecules Comprising the Antibody
EP4039705A1 (en) Antibody targeting bcma, bispecific antibody, and use thereof
JP2024531409A5 (cg-RX-API-DMAC7.html)
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2017526339A5 (cg-RX-API-DMAC7.html)
JP2022534135A5 (cg-RX-API-DMAC7.html)
JP2023093753A5 (cg-RX-API-DMAC7.html)
JP2023545183A5 (cg-RX-API-DMAC7.html)
JP2023545182A5 (cg-RX-API-DMAC7.html)
CN115819592B (zh) 靶向ror1的抗原结合蛋白
JP7679399B2 (ja) 抗flt3抗体及び組成物
JP2024546759A5 (cg-RX-API-DMAC7.html)
JP2021517459A5 (cg-RX-API-DMAC7.html)
JP2024516098A5 (cg-RX-API-DMAC7.html)
JP2023507740A5 (cg-RX-API-DMAC7.html)
JP2024527537A5 (cg-RX-API-DMAC7.html)
CN119923411A (zh) 靶向cd3的抗体及其用途
JP2024516621A5 (cg-RX-API-DMAC7.html)
CN111971303B (zh) 抗cd27抗体及其用途
AU2024201132A1 (en) Anti-mesothelin antibodies and uses thereof
JP2024527539A (ja) IL13Rα2を標的としたユニバーサルCAR-T細胞及びその製造方法と使用
CN120040594B (zh) 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用